//
Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Michael Goggins

M.B.B.Ch.
(410) 955-8964 (p)
Titles

Associate Professor of Pathology, Medicine, and Oncology
 

Training

Resident, Internal Medicine, St. James' Hospital, Dublin, IrelandClinical Fellow, Gastroenterology and Interanl Medicine, St. James' Hospital, Dublin, IrelandRes. Fellow, Cancer Genetics, The Johns Hopkins University School of Medicine
 

Research Summary

Discovering new markers of pancreatic adenocarcinoma To identify and characterize a panel of sensitive and specific pancreatic cancer markers, resected pancreatic cancers, pancreata affected by chronic pancreatitis, and normal pancreata are analyzed using a variety of approaches. Promising markers are then tested in the biologic fluids from patients with pancreatic cancer and from controls to identify their accuracy for pancreatic cancer and also to determine when such markers become manifest during pancreatic neoplastic development. The types of markers under investigation include aberrant DNA methylation and protein markers identified through global gene expression profiling and through proteomics approaches. 

 

Classifying pancreatic cancers by their methylator phenotypes These studies are aimed at at identifying mechanisms that contribute to the development of aberrant DNA methylation. We have also demonstrated that many genes are not only silenced by aberrant DNA hypermethylation during pancreatic cancer development, but that some genes that are overexpressed in pancreatic cancer lose their normal CpG methylation.

 

Familial Pancreatic Cancer We are investigating the familial basis of pancreatic cancer through linkage and candidate gene approaches.

 

We have identified several new serum markers of pancreatic cancer, including MIC-1 and osteopontin and proteomic peptides. We have also identified gene expression alterations that are associated with pancreatic neoplasia. Finally, we have identified several genes that are aberrantly silenced in pancreatic cancer that contribute to the malignant phenotype of pancreatic cancer.

 

Journal Citations

Abe, T., N. Fukushima, K. Brune, C. Boehm, N. Sato, H. Matsubayashi, M. Canto, G. M. Petersen, R. H. Hruban, and M. Goggins. 2007. Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms. Clin Cancer Res 13:6019-25.



Axilbund, J.E., Argani, P., Kamiyama, M., Palmisano, E., Raben, M., Borges, M., Brune, K.A., Goggins, M., Hruban, R.H., and Klein, A.P. (2009). Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer biology & therapy 8: Epub.



Bian, Y., Matsubayashi, H., Li, C. P., Abe, T., Canto, M., Murphy, K. M. & Goggins, M. (2006). Detecting low-abundance p16 and p53 mutations in pancreatic juice using a novel assay: heteroduplex analysis of limiting dilution PCRs. Cancer Biol Ther 5, 1392-9.



Brosens, L. A., J. J. Keller, L. Pohjola, C. Haglund, F. H. Morsink, C. Iacobuzio-Donahue, M. Goggins, F. M. Giardiello, A. Ristimaki, and G. J. Offerhaus. 2007. Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther 7.



Brosens, L. A., Keller, J. J., Offerhaus, G. J., Goggins, M. & Giardiello, F. M. (2005). Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut 54, 1034-43.



Brosens, L.A., Keller, J.J., Pohjola, L., Haglund, C., Morsink, F.H., Iacobuzio-Donahue, C., Goggins, M., Giardiello, F.M., Ristimaki, A., and Offerhaus, G.J. (2008). Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer biology & therapy 7, 424-427.



Brune, K., Abe, T., Canto, M., O'Malley, L., Klein, A. P., Maitra, A., Volkan Adsay, N., Fishman, E. K., Cameron, J. L., Yeo, C. J., Kern, S. E., Goggins, M. & Hruban, R. H. (2006). Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 30, 1067-76.



Brune, K., Hong, S.M., Li, A., Yachida, S., Abe, T., Griffith, M., Yang, D., Omura, N., Eshleman, J., Canto, M., Schulick, R., Klein, A.P., Hruban, R.H., Iacobuzio-Donohue, C., and Goggins, M. (2008). Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev 17, 3536-3542.



Canto, M. I., Goggins, M., Hruban, R. H., Petersen, G. M., Giardiello, F. M., Yeo, C., Fishman, E. K., Brune, K., Axilbund, J., Griffin, C., Ali, S., Richman, J., Jagannath, S., Kantsevoy, S. V. & Kalloo, A. N. (2006). Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4, 766-81; quiz 665.



Cao, D., Ashfaq, R., Goggins, M.G., Hruban, R.H., Kern, S.E., and Iacobuzio-Donahue, C.A. (2008). Differential Expression of Multiple Genes in Association with MADH4/DPC4/SMAD4 Inactivation in Pancreatic Cancer. International journal of clinical and experimental pathology 1, 510-517.



Cao, D., Q. Zhang, L. S. Wu, S. N. Salaria, J. W. Winter, R. H. Hruban, M. S. Goggins, J. L. Abbruzzese, A. Maitra, and L. Ho. 2007. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol 20:570-8.



Corso, C. D., Stubbs, D. D., Lee, S. H., Goggins, M., Hruban, R. H. & Hunt, W. D. (2006). Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor. Cancer Detect Prev 30, 180-7.



Couch, F. J., M. R. Johnson, K. G. Rabe, K. Brune, M. de Andrade, M. Goggins, H. Rothenmund, S. Gallinger, A. Klein, G. M. Petersen, and R. H. Hruban. 2007. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16:342-6.



Fukushima, N., Koopmann, J., Sato, N., Prasad, N., Carvalho, R., Leach, S. D., Hruban, R. H. & Goggins, M. (2005). Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol 18, 779-87.



Goggins, M. 2007. Disorders of the Small and Large Intestine. In S. S. Redonda Miller, Bimal Asher (ed.), The Johns Hopkins Internal Medicine Board Review, 2nd Edition ed, vol. In press. Mosby Publishers, Baltimore, MD.

Goggins, M. 2007. Genomics, Epigenomics and Proteomics of Pancreatic Cancer. In A. Lowy (ed.), Pancreatic Cancer, vol. In press.



Goggins, M. 2007. Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol 34:303-10.



Gronborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R., Reddy, R., Sato, N., Molina, H., Jensen, O. N., Hruban, R. H., Goggins, M. G., Maitra, A. & Pandey, A. (2006). Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5, 157-71.



Habbe, N., Koorstra, J.B., Mendell, J.T., Offerhaus, G.J., Ryu, J.K., Feldmann, G., Mullendore, M.E., Goggins, M.G., Hong, S.M., and Maitra, A. (2009). MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer biology & therapy 8, 340-346.



Hansel, D. E., Maitra, A., Lin, J. W., Goggins, M., Argani, P., Yeo, C. J., Piantadosi, S., Leach, S. D. & Biankin, A. V. (2005). Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. J Clin Oncol 23, 1811-8.



Harsha, H.C., Jimeno, A., Molina, H., Mihalas, A.B., Goggins, M.G., Hruban, R.H., Schulick, R.D., Kamath, U., Maitra, A., Hidalgo, M., and Pandey, A. (2008). Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. Journal of proteome research 7, 4651-4658.



Hong, S.M., Kelly, D., Griffith, M., Omura, N., Li, A., Li, C.P., Hruban, R.H., and Goggins, M. (2008). Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol 21, 1499-1507.



Hruban, R. H., A. Maitra, S.E. Kern and M. Goggins. 2007. Precursors to pancreatic cancer. In R. D. Odze (ed.), Gastroenterology Clinics of North America, vol. 36:831-49, vi. Elsevier Saunders.



Hruban, R. H., K. Takaori, M. Canto, E. K. Fishman, K. Campbell, K. Brune, S. E. Kern, and M. Goggins. 2007.

Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg 14:255-63.

Hruban, R. H., R.E. Wilentz, N. Fukushima and M. Goggins. 2007. Pancreas. In L. Weiss (ed.), Cancer Handbook. John Wiley & Sons, Ltd.



Hustinx, S. R., Fukushima, N., Zahurak, M. L., Riall, T. S., Maitra, A., Brosens, L., Cameron, J. L., Yeo, C. J., Offerhaus, G. J., Hruban, R. H. & Goggins, M. (2005). Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms. Cancer Biol Ther 4, 596-601.



Hustinx, S. R., Hruban, R. H., Leoni, L. M., Iacobuzio-Donahue, C., Cameron, J. L., Yeo, C. J., Brown, P. N., Argani, P., Ashfaq, R., Fukushima, N., Goggins, M., Kern, S. E. & Maitra, A. (2005). Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol Ther 4, 83-6.



Hustinx, S. R., Leoni, L. M., Yeo, C. J., Brown, P. N., Goggins, M., Kern, S. E., Hruban, R. H. & Maitra, A. (2005). Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol 18, 959-63.



Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S.M., Fu, B., Lin, M.T., Calhoun, E.S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D.R., Hidalgo, M., Leach, S.D., Klein, A.P., Jaffee, E.M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J.R., Kern, S.E., Hruban, R.H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V.E., and Kinzler, K.W. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, N.Y 321, 1801-1806.



Karanjawala, Z. E., P. B. Illei, R. Ashfaq, J. R. Infante, K. Murphy, A. Pandey, R. Schulick, J. Winter, R. Sharma, A. Maitra, M. Goggins, and R. H. Hruban. 2008. New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8. Am J Surg Pathol 32:188-196.



Karanjawala, Z. F., P.B. Illei, R. Ashfaq, J.R. Infante, K. Murphy, A. Pandey, Schulick, R.D., J. Winter, R. Sharma, A. Maitra, M. Goggins and R.H. Hruban. 2008. New markers of pancreatic cancer identified through differential gene expression analyses: Claudin 18 and Annexin A8. Am J Surg Pathol 32:188-196.



Karanjawala, Z.E., Illei, P.B., Ashfaq, R., Infante, J.R., Murphy, K., Pandey, A., Schulick, R., Winter, J., Sharma, R., Maitra, A., Goggins, M., and Hruban, R.H. (2008). New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. The American journal of surgical pathology 32, 188-196.



Klein, A. P., M. de Andrade, R. H. Hruban, M. Bondy, A. G. Schwartz, S. Gallinger, H. T. Lynch, S. Syngal, K. G. Rabe, M. G. Goggins, and G. M. Petersen. 2007. Linkage analysis of chromosome 4 in families with familial pancreatic cancer. Cancer Biol Ther 6:320-3.



Klein, A.P., Borges, M., Griffith, M., Brune, K., Hong, S-M., Omura, N., Hruban, R.H., and Goggins, M.G. (2009). Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 18, 1328-1330.



Koopmann, J., Rosenzweig, C. N., Zhang, Z., Canto, M. I., Brown, D. A., Hunter, M., Yeo, C., Chan, D. W., Breit, S. N. & Goggins, M. (2006). Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12, 442-6.



Lucito, R., S. Suresh, K. Walter, A. Pandey, B. Lakshmi, A. Krasnitz, J. Sebat, M. Wigler, A. P. Klein, K. Brune, E. Palmisano, A. Maitra, M. Goggins, and R. H. Hruban. 2007. Copy-Number Variants in Patients with a Strong Family History of Pancreatic Cancer. Cancer Biol Ther 6.



Martin, S. T., Matsubayashi, H., Rogers, C. D., Philips, J., Couch, F. J., Brune, K., Yeo, C. J., Kern, S. E., Hruban, R. H. & Goggins, M. (2005). Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24, 3652-6.



Matsubayashi, H., J. R. Infante, J. Winter, A. P. Klein, R. Schulick, R. Hruban, K. Visvanathan, and M. Goggins. 2007. Tumor COX-2 Expression and Prognosis of Patients with Resectable Pancreatic Cancer. Cancer Biol Ther 6.

Matsubayashi, H., Canto, M., Sato, N., Klein, A., Abe, T., Yamashita, K., Yeo, C. J., Kalloo, A., Hruban, R. & Goggins, M. (2006). DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 66, 1208-17.



Matsubayashi, H., Sato, N., Brune, K., Blackford, A. L., Hruban, R. H., Canto, M., Yeo, C. J. & Goggins, M. (2005). Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice. Clin Cancer Res 11, 573-83.



Nowak, N. J., Gaile, D., Conroy, J. M., McQuaid, D., Cowell, J., Carter, R., Goggins, M. G., Hruban, R. H. & Maitra, A. (2005). Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 161, 36-50.



Omura, N., Li, C.P., Li, A., Hong, S.M., Walter, K., Jimeno, A., Hidalgo, M., and Goggins, M. (2008). Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer biology & therapy 7, 1146-1156.



Parsi, M.A., Li, A., Li, C.P., and Goggins, M. (2008). DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. Clin Gastroenterol Hepatol 6, 1270-1278.



Petersen, G. M., de Andrade, M., Goggins, M., Hruban, R. H., Bondy, M., Korczak, J. F., Gallinger, S., Lynch, H. T., Syngal, S., Rabe, K. G., Seminara, D. & Klein, A. P. (2006). Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 15, 704-10.



Prasad, N. B., Biankin, A. V., Fukushima, N., Maitra, A., Dhara, S., Elkahloun, A. G., Hruban, R. H., Goggins, M. & Leach, S. D. (2005). Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 65, 1619-26.



Rogers, C. D., Fukushima, N., Sato, N., Shi, C., Prasad, N., Hustinx, S. R., Matsubayashi, H., Canto, M., Eshleman, J. R., Hruban, R. H. & Goggins, M. (2006). Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs. Cancer Biol Ther 5, 1383-9.



Salaria, S. N., P. Illei, R. Sharma, K. M. Walter, A. P. Klein, J. R. Eshleman, A. Maitra, R. Schulick, J. Winter, M. M. Ouellette, M. Goggins, and R. Hruban. 2007. Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biol Ther 6:324-8.



Sato, N., Fukushima, N., Hruban, R.H., and Goggins, M. (2008). CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol 21, 238-244.



Schmidt, C. M., M. T. Yip-Schneider, M. C. Ralstin, S. Wentz, J. Dewitt, S. Sherman, T. J. Howard, L. McHenry, S. Dutkevitch, M. Goggins, A. Nakeeb, and K. D. Lillemoe. 2007. PGE(2) in Pancreatic Cyst Fluid Helps Differentiate IPMN from MCN and Predict IPMN Dysplasia. J Gastrointest Surg.



Schmidt, C.M., Yip-Schneider, M.T., Ralstin, M.C., Wentz, S., DeWitt, J., Sherman, S., Howard, T.J., McHenry, L., Dutkevitch, S., Goggins, M., Nakeeb, A., and Lillemoe, K.D. (2008). PGE(2) in pancreatic cyst fluid helps differentiate IPMN from MCN and predict IPMN dysplasia. J Gastrointest Surg 12, 243-249.



Shi, C., Fukushima, N., Abe, T., Bian, Y., Hua, L., Wendelburg, B.J., Yeo, C.J., Hruban, R.H., Goggins, M.G., and Eshleman, J.R. (2008). Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer biology & therapy 7, 353-360.



Shi, C., Hong, S.M., Lim, P., Kamiyama, H., Khan, M., Anders, R.A., Goggins, M., Hruban, R.H., and Eshleman, J.R. (2009). KRAS2 Mutations in Human Pancreatic Acinar-Ductal Metaplastic Lesions Are Limited to Those with PanIN: Implications for the Human Pancreatic Cancer Cell of Origin. Mol Cancer Res Epub.



Shi, C., N. Fukushima, T. Abe, Y. Bian, L. Hua, B. J. Wendelburg, C. J. Yeo, R. H. Hruban, M. G. Goggins, and J. R. Eshleman. 2007. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 7.



Song, J., Patel, M., Rosenzweig, C. N., Chan-Li, Y., Sokoll, L. J., Fung, E. T., Choi-Miura, N. H., Goggins, M., Chan, D. W. & Zhang, Z. (2006). Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 52, 1045-53.



Tan, A.C., Fan, J.B., Karikari, C., Bibikova, M., Garcia, E.W., Zhou, L., Barker, D., Serre, D., Feldmann, G., Hruban, R.H., Klein, A.P., Goggins, M., Couch, F.J., Hudson, T.J., Winslow, R.L., Maitra, A., and Chakravarti, A. (2008). Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery. Cancer biology & therapy 7, 135-144.



van Hattem, W.A., Carvalho, R., Li, A., Offerhaus, G.J., and Goggins, M. (2008). Amplification of EMSY Gene in a Subset of Sporadic Pancreatic Adenocarcinomas. International journal of clinical and experimental pathology 1, 343-351.



Walter, K., Omura, N., Hong, S.M., Griffith, M., and Goggins, M. (2008). Pancreatic cancer associated fibroblasts display normal allelotypes. Cancer biology & therapy 7, 882-888.

Brosens, L. A., Iacobuzio-Donahue, C. A., Keller, J. J., Hustinx, S. R., Carvalho, R., Morsink, F. H., et al. 2005. Increased cyclooxygenase-2 expression in duodenal compared to colonic tissues in familial adenomatous polyposis and relationship to the -765G>C COX-2 polymorphism. Clin. Cancer Res. 11:4090-4096.



Cao, D., Hustinx, S. R., Sui, G., Bala, P., Sato, N., Martin, S., et al. 2004. Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. Cancer Biol. Ther. 3:1081-1089. [Discussion, pp. 1090-1091].

Fukushima, N., Koopmann, J., Sato, N., Prasad, N., Carvalho, R., Leach, S. D., et al. 2005. Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Modern Pathol. 18:779-787.

Fukushima, N., Sato, N., Prasad, N., Leach, S. D., Hruban, R. H., & Goggins, M. S. 2004. Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide-microarrays. Oncogene. 23:9042-9051.

Gronborg, M., Bunkenborg, J., Kristiansen, T. Z., Jensen, O. N., Yeo, C. J., Hruban, R. H., et al. 2004. Comprehensive proteomic analysis of human pancreatic juice. J. Proteome Res. 3:1042-1055.

Grønborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R., Reddy, R., Sato, N., et al. 2005. Biomarker discovery from pancreatic cancer secretome using a differential proteomics approach. Mol. Cell. Proteomics. [Oct. Epub ahead of print].



Hansel, D. E., Maitra, A., Lin, J. W., Goggins, M., Argani, P., Yeo, C. J., et al. 2005. Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. J. Clin. Oncol. 23:1811-1818.

Hruban, R. H., Takaori, K., Klimstra, D. S., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., et al. 2004. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol. 28:977-987.

Hustinx, S. R., Cao, D., Maitra, A., Sato, N., Martin, S. T., Sudhir, D., et al. 2004. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol. Ther. 3:1254-1261.

Hustinx, S. R., Fukushima, N., Zahurak, M. L., Riall, T. S., Maitra, A., Brosens, L. A. A., et al. 2005. Expression and prognostic significance of 14-3-3 sigma and ERM family protein expression in periampullary neoplasms. Cancer Biol. Ther. 4:596-601.

Hustinx, S. R., Hruban, R. H., Leoni, L. M., Iacobuzio-Donahue, C. A., Cameron, J. L., Yeo, C. J., et al. 2005. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol. Ther. 4:83-86.

Hustinx, S. R., Leoni, L. M., Yeo, C. J., Brown, P. N., Goggins, M. G., Kern, S. E., et al. 2005. Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Modern Pathol. 18:959-963.

Iacobuzio-Donahue, C. A., van der Heijden, M. S., Baumgartner, M. R., Troup, W. J., Romm, J. M., Doheny, K., et al. 2004. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res. 64:871-875.

Koopmann, J., Buckhaults, P., Brown, D. A., Zahurak, M. L., Sato, N., Fukushima, N., et al. 2004. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin. Cancer Res. 10:2386-2392.

Koopmann, J., Rosenzweig, C. N., Zhang, Z., Canto, M. I., Brown, D. A., Hunter, D. A., et al. Serum markers in patients with resectable pancreatic adenocarcinoma: MIC-1 vs. CA19-9. Clin. Cancer Res. [In press].

Koopmann, J., Thuluvath, P. J., Zahurak, M. L., Kristiansen, T. Z., Pandey, A., Schulick, R., et al. 2004. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer. 101:1609-1615.

Koopmann, J., Zhang, Z., White, N., Rosenzweig, J., Fedarko, N., Jagannath, S., et al. 2004. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res. 10:860-868.

Kristiansen, T. Z., Bunkenborg, J., Gronborg, M., Molina, H., Thuluvath, P. J., Argani, P., et al. 2004. A proteomic analysis of human bile. Mol. Cell. Proteomics. 3:715-728.

Maitra, A., Cohen, Y., Gillespie, S. E., Mambo, E., Fukushima, N., Hoque, M. O., et al. 2004. The human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res. 14:812-819.

Martin, S. T., Matsubayashi, H., Rogers, C. D., Philips, J., Couch, F. J., Brune, K., et al. 2005. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene. 24:3652-3656.



Martin, S. T., Sato, N., Dhara, S., Chang, R., Hustinx, S. R., Abe, T., et al. 2005. Aberrant methylation of the human hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biol. Ther. 4:728-733.



Matsubayashi, H., Canto, M., Sato, N., Klein, A., Abe, T., Yamashita, K., et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. [In press].

Matsubayashi, H., Sato, N., Brune, K., Blackford, A. L., Hruban, R. H., Canto, M., et al. 2005. Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice. Clin. Cancer Res. 11:573-583.

Matsubayashi, H., Skinner, H. G., Iacobuzio-Donahue, C. A., Abe, T., Sato, N., Riall, T. S., et al. 2005. Pancreaticobiliary cancers with deficient methylenetetrahydrofolate reductase genotypes. Clin. Gastroenterol. Hepatol. 3:752-760.



Nowak, N. J., Gaile, D., Conroy, J. M., McQuaid, D., Cowell, J., Carter, R., et al. 2005. Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet. Cytogen. 161:36-50.



Prasad, N. B., Biankin, A. V., Fukushima, N., Maitra, A., Dhara, S., Elkahloun, A. G., et al. 2005. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 65:1619-1626.

Rogers, C., van der Heijden, M. S., Brune, K., Yeo, C. J., Hruban, R. H., Kern, S. E., et al. 2004. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol. Ther. 3:16709.

Sato, N., Fukushima, N., Chang, R., Matsubayashi, H., & Goggins, M. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology. [In press].

Sato, N., Fukushima, N., Matsubayashi, H., & Goggins, M. S. 2004. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 23:1531-1538.

Sato, N., Maehara, N., & Goggins, M. S. 2004. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res. 64:6950-6956.

Sato, N., Matsubayashi, H., Abe, T., Fukushima, N., & Goggins, M. G. 2005. Epigenetic downregulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin. Cancer Res. 11:4681-4688.

Sato, N., Matsubayashi, H., Fukushima, N., & Goggins, M. G. 2005. The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer. Cancer Biol. Ther. 4:70-76.

Sato, N., Parker, A. R., Fukushima, N., Miyagi, Y., Iacobuzio-Donahue, C. A., Eshleman, J. R., et al. 2004. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene. 24:850-858.

Shi, C., Eshleman, S. H., Jones, D., Fukushima, N., Hua, L., Parker, A. R., et al. 2004. LigAmp for sensitive detection of single-nucleotide differences. Nat. Methods. 1:141-147.

Van Heek, N. T., Maitra, A., Koopmann, J., Fedarko, N., Jain, A., Rahman, A., et al. 2004. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol. Ther. 3:7.

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer